Evidence map›Paper›PMID 40331226›Full record

ArticleThe World Allergy Organization journal2025

Total IgE levels in patients with hematologic malignancies.

Parisa Amjadi, Fatemehsadat Hosseini, Ehsan Zaboli, Mohammad Eslami-Jouybari, Hossein Asgarian-Omran, Akbar Hedayatizadeh-Omran, Versa Omrani-Nava, Reza Alizadeh-Navaei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Comment on "Total IgE and hematologic malignancy development".The World Allergy Organization journal · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa AmjadiGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Fatemehsadat HosseiniGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Ehsan ZaboliGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad Eslami-JouybariGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Hossein Asgarian-OmranDepartment of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Akbar Hedayatizadeh-OmranGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Versa Omrani-NavaGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Reza Alizadeh-NavaeiGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune system compartments have a crucial role in the progression or suppression of cancer. Hematologic malignancies are among the most common cancers, and there is conflicting research regarding the role of their relationship with allergies and IgE levels. This study aimed to compare total IgE levels in patients with hematologic malignancies to those in non-cancer controls. Methods: In this cross-sectional study in 2023, sixty patients with hematological malignancies and 90 non-cancer patients attending Sari Imam Hospital were evaluated for total IgE levels along with demographic data. The convenience sampling method was used for the selection of both patients and controls. IgE levels were measured in both groups ELISA method. The analysis was performed using SPSS 20. Results: The most common types of malignancy were ALL (23.3%) and multiple myeloma (23.3%). The median IgE level in patients (7.08, IQR:2.07-19.07) was significantly lower than the control group (42.41, IQR:11.99-145.57). The odds ratio for hematological malignancy associated with low total IgE was 6.79 (CI 95%: 2.90-15.92). After adjusting for age and sex, the adjusted odds ratio increased to 15.89 (CI 95%: 4.14-60.95). Conclusion: Patients with hematological cancers have significantly lower IgE levels compared with individuals with no cancer.

Indexed as

AllergyHematologic malignanciesTotal IgE

Identifiers

PMID40331226
PMCPMC12051143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.